1-2 of 2
Shulamiet Wittebol, MD, PhD
Close
Sort by
Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 287.
https://doi.org/10.1182/blood.V122.21.287.287
Published: 2013
Journal Articles

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Gerard M.J. Bos, MD, PhD, Sandra Croockewit, MD, PhD, Jan J. Cornelissen, MD, PhD, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, MD, PhD, Michel Delforge, MD, PhD, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, MD, PhD, Edo Vellenga, MD, PhD, Asiong Jie, Henriette Berenschot, MD, PhD, Marinus Marwijk-kooy, MD, PhD, Pieter Sonneveld, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 157.
https://doi.org/10.1182/blood.V112.11.157.157
Published: 2008